Navigation Links
VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
Date:8/1/2008

SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, MD, VIA's senior vice president of research and development, will present at the 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress taking place August 4-7 in Boston, MA.

The presentation details are as follows:

Date/Time: Wednesday, August 6, 2008: 2:20-2:50 p.m. ET

Location: World Trade Center Boston & Seaport Hotel

Session: Translational Medicine IV: Case Studies of Translational

Approaches from Preclinical to Clinical Proof-of-Concept

Title: Innovative Clinical Trial and Biomarker Approaches To Demonstrate

the Role Of Leukotrienes and 5LO Inhibition in Atherosclerotic Disease

"VIA has taken an innovative approach in its design of Phase 2 clinical trials for VIA-2291, its lead compound," said Dr. Taub. "I am excited to share with conference participants our view on the value of innovative techniques in the design of critical clinical trials, particularly with regards to serum inflammatory biomarkers, analyses of atherosclerotic plaque tissue, and non-invasive imaging."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
2. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
3. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
5. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
8. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
9. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial ... The net income for the first quarter ended March ... of $14.1 million during the same period in 2010. Net ... related primarily to the $34.2 million in collaboration revenue recognized ...
... 2011 Silence Therapeutics plc (AIM: ... of patent 4,705,370, titled "Further Novel Forms of ...  The issued patent covers aspects of Silence,s platform ... 2,-O-Methyl structures known as AtuRNAi.  Silence,s AtuRNAi molecules ...
... May 2, 2011 Dendreon Corporation (Nasdaq: DNDN ) ... Revenue for the quarter ended March 31, 2011 was $28.1 million ... The GAAP net loss for the quarter ended March ... $125.7 million, or $0.96 per share for the quarter ended March ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 2Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 3Dendreon Reports First Quarter 2011 Financial Results 2Dendreon Reports First Quarter 2011 Financial Results 3Dendreon Reports First Quarter 2011 Financial Results 4Dendreon Reports First Quarter 2011 Financial Results 5
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... male managers power dress, posture and exercise power is ... the University of New South Wales (UNSW). Prehistoric ... as their "turf" and ostracising those who do not ... work situations than many of us want to accept, ...
... breaks in the two strands of the DNA double helix ... a molecular machine called the MRN complex is responsible for ... method of DNA repair called homologous recombination. In ... the journal Cell , John Tainer of the Life ...
... cells commute. To get from their birthplace to their ... an elaborate track of exceptionally strong proteins known as ... the October 3 issue of Cell , scientists ... show that a molecule, called ACF7, helps regulate and ...
Cached Biology News:Why your boss is white, middle-class and a show-off 2The structure of the Mre11 protein bound to DNA 2The structure of the Mre11 protein bound to DNA 3The structure of the Mre11 protein bound to DNA 4The structure of the Mre11 protein bound to DNA 5The structure of the Mre11 protein bound to DNA 6Scientists identify a molecule that coordinates the movement of cells 2
Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....
Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
...
Biology Products: